ArticleBlood cell therapy2025
Salvage UCBT with Short-Term Melphalan-based Reduced-Intensity Conditioning for Primary Graft Failure after Upfront UCBT for Fulminant Aplastic Anemia.
Article in Blood cell therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Umbilical cord blood transplantation (UCBT) is a potential option for patients with very severe aplastic anemia (VSAA) when no suitable related or unrelated donor is available. However, the high incidence of graft failure following UCBT remains a major challenge. The optimal conditioning regimen for UCBT in aplastic anemia (AA), particularly for salvage UCBT after graft failure following an initial transplant, remains undetermined. We report the cases of two adolescent patients with fulminant aplastic anemia who successfully underwent salvage UCBT, conditioned by a short-term melphalan-based regimen for primary graft failure after initial UCBT. The regimen comprised fludarabine (30 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.